Compare Oatly Group AB - ADR (OTLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs TransMedics Group Inc — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while TransMedics Group Inc trades at $78.19 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.3× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and TransMedics Group Inc for 24 Days on average.
| OTLY | TMDX | |
|---|---|---|
Market Cap | $330.93M | $2.74B |
Volume | 68,708 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $150.42 |
52-Week Low | $8.03 | $61.99 |
Typical Hold Time | 18 Days | 24 Days |
Enterprise Value | $835.34M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
